Area of research
Management of Technology and Innovation · Biochemistry
Research interest
Research focused on Convalescent plasma and Coronavirus disease 2019 (COVID-19), with related work in Randomized controlled trial, Asymptomatic, Hepatocellular carcinoma. Notable publications include 'High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis', 'Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19', and 'SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020'.
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial
Ecological and clinical evidence of the establishment of West Nile virus in a large urban area in Europe, Berlin, Germany, 2021 to 2022
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19
SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020
Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis